JP2022552254A5 - - Google Patents
Info
- Publication number
- JP2022552254A5 JP2022552254A5 JP2022521217A JP2022521217A JP2022552254A5 JP 2022552254 A5 JP2022552254 A5 JP 2022552254A5 JP 2022521217 A JP2022521217 A JP 2022521217A JP 2022521217 A JP2022521217 A JP 2022521217A JP 2022552254 A5 JP2022552254 A5 JP 2022552254A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- nucleic acid
- acid construct
- construct according
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025167212A JP2026021331A (ja) | 2019-10-10 | 2025-10-03 | バリアントigf2構築体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913677P | 2019-10-10 | 2019-10-10 | |
| US62/913,677 | 2019-10-10 | ||
| US201962929054P | 2019-10-31 | 2019-10-31 | |
| US62/929,054 | 2019-10-31 | ||
| PCT/US2020/055251 WO2021072372A1 (en) | 2019-10-10 | 2020-10-12 | Variant igf2 constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167212A Division JP2026021331A (ja) | 2019-10-10 | 2025-10-03 | バリアントigf2構築体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552254A JP2022552254A (ja) | 2022-12-15 |
| JP2022552254A5 true JP2022552254A5 (cg-RX-API-DMAC7.html) | 2023-10-20 |
Family
ID=75438187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521217A Pending JP2022552254A (ja) | 2019-10-10 | 2020-10-12 | バリアントigf2構築体 |
| JP2025167212A Pending JP2026021331A (ja) | 2019-10-10 | 2025-10-03 | バリアントigf2構築体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167212A Pending JP2026021331A (ja) | 2019-10-10 | 2025-10-03 | バリアントigf2構築体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240091321A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4041284A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022552254A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220077921A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115087458A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020361703A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022006842A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3154189A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292065A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022004345A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202128740A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021072372A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202344691A (zh) * | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| EP4359430A4 (en) | 2021-06-23 | 2025-07-16 | Lycia Therapeutics Inc | BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES |
| AU2023303015A1 (en) * | 2022-07-06 | 2025-01-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
| US20260216373A1 (en) * | 2023-01-13 | 2026-07-30 | Amicus Therapeutics, Inc. | Gene Therapy Constructs for the Treatment of Pompe Disease |
| AU2024241509A1 (en) * | 2023-03-20 | 2025-09-25 | Spark Therapeutics, Inc. | Ppt1 gene therapy |
| US20240360431A1 (en) * | 2023-04-30 | 2024-10-31 | Sichuan Real&Best Biotech Co., Ltd. | Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease |
| PL445164A1 (pl) * | 2023-06-07 | 2024-12-09 | Recepton Spółka Z Ograniczoną Odpowiedzialnością | Cząsteczki indukujące internalizację receptorów i białek zewnątrzkomórkowych |
| CN120025420A (zh) * | 2023-11-21 | 2025-05-23 | 深圳湾实验室 | 用于蛋白降解的构建体及其应用 |
| WO2025259950A1 (en) * | 2024-06-14 | 2025-12-18 | Cz Biohub Sf, Llc | Genetically encoded lysosome targeting chimeras for cell-mediated delivery |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1436316B1 (en) * | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| DE602005020745D1 (de) * | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| AU2006203882B2 (en) * | 2005-01-07 | 2011-05-12 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
| LT2714752T (lt) * | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| WO2014082080A2 (en) * | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| ES2679374T3 (es) * | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| EP2976092B1 (en) * | 2013-03-15 | 2020-04-22 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
| WO2016025523A1 (en) * | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| EP3374504B1 (en) * | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| WO2018035563A1 (en) * | 2016-08-24 | 2018-03-01 | Immunexpress Pty Ltd | Systemic inflammatory and pathogen biomarkers and uses therefor |
| TW202344691A (zh) * | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| US20220193261A1 (en) * | 2019-04-30 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of pompe disease |
-
2020
- 2020-10-12 JP JP2022521217A patent/JP2022552254A/ja active Pending
- 2020-10-12 TW TW109135159A patent/TW202128740A/zh unknown
- 2020-10-12 MX MX2022004345A patent/MX2022004345A/es unknown
- 2020-10-12 CN CN202080081564.6A patent/CN115087458A/zh active Pending
- 2020-10-12 US US17/767,803 patent/US20240091321A1/en active Pending
- 2020-10-12 EP EP20875073.7A patent/EP4041284A4/en active Pending
- 2020-10-12 CA CA3154189A patent/CA3154189A1/en active Pending
- 2020-10-12 BR BR112022006842A patent/BR112022006842A2/pt not_active Application Discontinuation
- 2020-10-12 AU AU2020361703A patent/AU2020361703A1/en not_active Abandoned
- 2020-10-12 WO PCT/US2020/055251 patent/WO2021072372A1/en not_active Ceased
- 2020-10-12 KR KR1020227015116A patent/KR20220077921A/ko not_active Ceased
-
2022
- 2022-04-07 IL IL292065A patent/IL292065A/en unknown
-
2025
- 2025-02-01 AU AU2025200698A patent/AU2025200698A1/en active Pending
- 2025-10-03 JP JP2025167212A patent/JP2026021331A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220127326A1 (en) | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof | |
| JP2007523648A5 (cg-RX-API-DMAC7.html) | ||
| ES2613691T3 (es) | Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal | |
| JP2021521851A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524662A5 (cg-RX-API-DMAC7.html) | ||
| KR102946363B1 (ko) | 치료학적 효소류의 결합체 | |
| Aronson Jr et al. | Lysosomal degradation of Asn‐linked glycoproteins | |
| US9932568B2 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| EP1981546B1 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
| EP1587923B1 (en) | Improved constructs for expressing lysosomal polypeptides | |
| ES2629853T3 (es) | Péptidos de dirección lisosómica y usos de los mismos | |
| US20080241118A1 (en) | Methods and Compositions for Targeting Proteins Across the Blood Brain Barrier | |
| JP2011521627A5 (cg-RX-API-DMAC7.html) | ||
| IL275248B2 (en) | A therapeutic enzyme fusion protein with a novel structure and its use | |
| KR20110089193A (ko) | 식물 배양에서 고-만노스 단백질의 생산 | |
| JP2022512689A5 (cg-RX-API-DMAC7.html) | ||
| JP6594833B2 (ja) | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 | |
| EP1480510B1 (en) | Expression of lysosomal enzymes in plant seeds | |
| JP7791517B2 (ja) | ライソゾームを標的とした新規ddsの開発 | |
| US20060188975A1 (en) | Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders | |
| Sakuraba et al. | Molecular pathologies of and enzyme replacement therapies for lysosomal diseases | |
| Anson et al. | Sulphamidase | |
| US20200206323A1 (en) | An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases | |
| RU2023123291A (ru) | Антитела против рецептора трансферрина и их применение | |
| Marković-Housley et al. | MECHANISM OF BEE VENOM HYALURONIDASE, A MAJOR |